We are live on ! Find out more
PBLA

Panbela Therapeutics, Inc. Common Stock
PBLA

Delisted

PBLA was delisted on the 6th of March, 2024.

Back to rankings

4 hedge funds and large institutions have $1.02M invested in Panbela Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
4
Holders Change
+4
Holders Change %
–
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WVP
Worth Venture Partners
New Jersey
+$350K
2
CH
CVI Holdings
Delaware
+$210K
3
EIM
Essex Investment Management
Massachusetts
+$210K
4
Verition Fund Management
Verition Fund Management
Connecticut
+$210K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
WVP
1
Worth Venture Partners
New Jersey
$372K +$350K +5 New
CH
2
CVI Holdings
Delaware
$238K +$210K +3 New
EIM
3
Essex Investment Management
Massachusetts
$231K +$210K +3 New
Verition Fund Management
4
Verition Fund Management
Connecticut
$182K +$210K +3 New

PBLA Hedge Fund Activity: Q3 2020 in Review

4 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Panbela Therapeutics, Inc. Common Stock (PBLA) for Q3 2020, worth a combined $1.02M.

Buyers outnumbered sellers: 4 funds opened new PBLA positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Worth Venture Partners, opening a new position worth an estimated $350K.

  • 4 institutional investors held Panbela Therapeutics, Inc. Common Stock (PBLA) as of Q3 2020, up from 0 in Q2 2020.
  • Funds reported $1.02M of Panbela Therapeutics, Inc. Common Stock stock for Q3 2020.
  • 4 funds opened new Panbela Therapeutics, Inc. Common Stock positions in Q3 2020 and 0 closed out, a net change of +4 holders.
  • The largest Panbela Therapeutics, Inc. Common Stock buyer in Q3 2020 was Worth Venture Partners, an estimated $350K added.

Based on aggregated 13F filings for Q3 2020.